BioWorld

Feb. 25, 2003

VaxGen's AIDS Vaccine Comes Up Short; Blacks, Asians Show Benefit

VaxGen Inc. did not receive the results it and so many others hoped for after releasing Phase III trial data for its experimental AIDS vaccine, resulting in an investment backlash against the company's stock. (BioWorld Today) Read More

Trimeris, Roche Implement Program In Europe, Set Price

Monocyte Cells, Easily Accessible To Draw From Blood, Can Double For Dicey Embryonic Stem Cells

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...